

News Release

1 August 2013

Biofrontera AG appoints M.M.Warburg & CO as new Designated Sponsor

For further information please contact:

Anke zur Muehlen
Director PR/IR

+ 49 214 87632 0
+ 49 214 87632 90
a.zurmuehlen@biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

Leverkusen, Germany – Biofrontera AG (DSE: B8F) has, effective August 1, 2013, appointed M.M.Warburg & CO as new Designated Sponsor.

Established in Hamburg in 1798, M.M.Warburg & CO is now one of the largest private banks in Germany. The Department of Designated sponsoring currently works with over 25 companies. It is regularly awarded an A/A-rating by the Deutsche Börse. With subsidiary banks and holding companies, the Warburg bank group is represented in many locations in Germany and neighbouring countries.

As Designated Sponsor, M.M.Warburg & CO will provide liquidity to the ongoing trading of the company's shares on the XETRA system through binding bid and offer quotes. In addition, M.M.Warburg & CO will prepare research on Biofrontera and assist the company in its efforts to reach out to investors, in Germany and overseas.

“M.M.Warburg & CO's expertise and its international network makes it an ideal partner as Designated Sponsor for an internationally expanding company such as Biofrontera. Appointing Thomas Schaffer as new CFO and now mandating M.M.Warburg & CO are consequent steps towards growing and further internationalizing Biofrontera group,” explained Prof. Hermann Lübbert, CEO of Biofrontera AG.

Biofrontera AG

Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection.

Biofrontera AG is listed on the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113.

www.biofrontera.com

News Release

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

For further information please contact:

Anke zur Muehlen
Director PR/IR

+ 49 214 87632 0
+ 49 214 87632 90
a.zurmuehlen@biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany